These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

236 related items for PubMed ID: 19028406

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Meta-analysis of dermatological toxicities associated with sorafenib.
    Zhang L, Zhou Q, Ma L, Wu Z, Wang Y.
    Clin Exp Dermatol; 2011 Jun; 36(4):344-50. PubMed ID: 21507035
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.
    Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, De Greve J, Douillard JY, Lathia C, Schwartz B, Taylor I, Moscovici M, Saltz LB.
    J Clin Oncol; 2006 Sep 10; 24(26):4293-300. PubMed ID: 16908937
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma.
    Akaza H, Tsukamoto T, Murai M, Nakajima K, Naito S.
    Jpn J Clin Oncol; 2007 Oct 10; 37(10):755-62. PubMed ID: 17951335
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Eruptive keratoacanthoma-type squamous cell carcinomas in patients taking sorafenib for the treatment of solid tumors.
    Smith KJ, Haley H, Hamza S, Skelton HG.
    Dermatol Surg; 2009 Nov 10; 35(11):1766-70. PubMed ID: 19660024
    [Abstract] [Full Text] [Related]

  • 15. Safety and anti-tumor activity of sorafenib (Nexavar) in combination with other anti-cancer agents: a review of clinical trials.
    Takimoto CH, Awada A.
    Cancer Chemother Pharmacol; 2008 Apr 10; 61(4):535-48. PubMed ID: 18026728
    [Abstract] [Full Text] [Related]

  • 16. Successful topical treatment of sorafenib-induced hand-foot skin reaction in a child with hepatocellular carcinoma.
    Hütten M, Lassay L, Sachs B, Deutz P, Mertens R, Baron JM, Merk HF, Ott H.
    Pediatr Dermatol; 2009 Apr 10; 26(3):349-50. PubMed ID: 19706105
    [Abstract] [Full Text] [Related]

  • 17. Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer.
    Blumenschein GR, Gatzemeier U, Fossella F, Stewart DJ, Cupit L, Cihon F, O'Leary J, Reck M.
    J Clin Oncol; 2009 Sep 10; 27(26):4274-80. PubMed ID: 19652055
    [Abstract] [Full Text] [Related]

  • 18. Sorafenib: a promising new targeted therapy for renal cell carcinoma.
    Wood LS, Manchen B.
    Clin J Oncol Nurs; 2007 Oct 10; 11(5):649-56. PubMed ID: 17962173
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.